

# Imugene Ltd

17:16 02 Dec 2019

## Imugene's immunotherapy strategy given stamp of approval in oversubscribed placement

Imugene Limited (ASX:IMU) has received strong support from sophisticated and professional investors for an A\$24.6 million share placement that has been oversubscribed.

This capital raising fully funds the company's clinical programs, including the two oncolytic virotherapy candidates and B-cell immunotherapy candidates, through key value inflection points.

Both platforms are now funded through to meaningful proof of concept for corporate partnering discussions.

683 million shares to be placed

The placement of up to 683 million ordinary shares at A3.6 cents per share was well supported by existing investors and new sophisticated and institutional investors.

It also includes one new option for every three new shares issued with an exercise price of A5.4 cents per new option exercisable on or before November 30, 2022.

"Overwhelming response"

Imugene's managing director and CEO Leslie Chong said, "We are pleased with the overwhelming response to the placement across many geographies with strong interest expressed in Imugene's recently acquired oncolytic virus CF33 which was developed at the City of Hope Cancer Centre in California.

"Investor appetite well exceeded the company's placement capacity."

She said, "With our existing cash reserves of A\$16 million, this placement allows Imugene to deliver on all clinical trials currently running and planned to commence in 2020."

Funding clinical programs

The capital raising proceeds are expected to fund Imugene's existing clinical programs including the two oncolytic virus clinical candidates through completion of Phase 2 study and to provide working capital.

A combination of the capital raising and current financial position supports the oncolytic virotherapy platform and B-cell immunotherapy through to meaningful proof of concept for corporate partnering discussions.

This placement also includes one new option for every three new shares issued with an exercise price of 5.4 cents per new option exercisable on or

**Price:** 0.035

**Market Cap:** \$154.91 m

### 1 Year Share Price Graph



### Share Information

**Code:** IMU

**Listing:** ASX

**52 week High Low**  
0.063 0.013

**Sector:** Pharma & Biotech

**Website:** www.imugene.com

### Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

before November 30, 2022.

19.8% discount to VWAP

The placement price represents a 19.8% discount to the weighted average closing price of shares over the previous 30 trading days to November 27, 2019.

Bell Potter Securities Limited acted as lead manager for the placement, with Aurenda Partners as co-manager and Roth Capital Partners as US placement agent.

Placement shares will be issued under the company's existing capacity as per ASX Listing Rule 7.1 and 7.1A.

Imugene is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

The technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).